Cardiovascular benefits of lowering blood pressure

被引：15

作者：

Weber, Michael A. ^{[1
]}

Lackland, Daniel T. ^{[2
]}

机构：

[1] State Univ New York, Downstate Coll Med, 450 Clarkson Ave,POB 97, Brooklyn, NY 11203 USA

[2] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA

来源：

NATURE REVIEWS NEPHROLOGY | 2016年 / 12卷 / 04期

关键词：

MORTALITY; EVENTS;

D O I：

10.1038/nrneph.2016.27

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

A recent meta-analysis reports that blood-pressure-lowering treatments reduce the rate of cardiovascular events in patients with baseline systolic blood pressures ranging from >160 mmHg to <130 mmHg. Notwithstanding their diverse data sources, the researchers assert that a blood pressure target of <130 mmHg should be adopted when treating hypertension.

引用

页码：202 / 204

页数：3

共 50 条

[31] Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
Inzucchi, Silvio E.
Fitchett, David
Jurisic-Erzen, Dubravka
Woo, Vincent
Hantel, Stefan
Janista, Christina
Kaspers, Stefan
George, Jyothis T.
Zinman, Bernard
DIABETES OBESITY & METABOLISM, 2020, 22 (04) : 631 - 639
[32] Pros and Cons of Intensive Systolic Blood Pressure Lowering
Kramer, Holly
Cooper, Richard
CURRENT HYPERTENSION REPORTS, 2018, 20 (02)
[33] Pros and Cons of Intensive Systolic Blood Pressure Lowering
Holly Kramer
Richard Cooper
Current Hypertension Reports, 2018, 20
[34] Invasively Measured Aortic Systolic Blood Pressure and Office Systolic Blood Pressure in Cardiovascular Risk Assessment in CKD
Peters, Christian D.
Olesen, Kevin K. W.
Laugesen, Esben
Maeng, Michael
Botker, Hans Erik
Poulsen, Per L.
Buus, Niels Henrik
KIDNEY INTERNATIONAL REPORTS, 2024, 9 (02): : 296 - 311
[35] Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressure-lowering treatment: a retrospective cohort study
Herrett, Emily
Gadd, Sarah
Jackson, Rod
Bhaskaran, Krishnan
Williamson, Elizabeth
van Staa, Tjeerd
Sofat, Reecha
Timmis, Adam
Smeeth, Liam
LANCET, 2019, 394 (10199) : 663 - 671
[36] The Efficacy of Antihypertensive Drugs in Lowering Blood Pressure and Cardiovascular Events in the Elderly Population: A Systematic Review and Meta-Analysis
Chaudhry, Raheel
Siddique, Yusuf A.
Sebai, Ahmad
Moazam, Mustafa M.
Virk, Ghazala S.
Tamene, Yonas
Hassouba, Mohamed
CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (01)
[37] Influence of Time of Day of Blood Pressure-Lowering Treatment on Cardiovascular Risk in Hypertensive Patients With Type 2 Diabetes
Hermida, Ramon C.
Ayala, Diana E.
Mojon, Artemio
Fernandez, Jose R.
DIABETES CARE, 2011, 34 (06) : 1270 - 1276
[38] Cost-Effectiveness of Enhancing Adherence to Therapy with Blood Pressure-Lowering Drugs in the Setting of Primary Cardiovascular Prevention
Scotti, Lorenza
Baio, Gianluca
Merlino, Luca
Cesana, Giancarlo
Mancia, Giuseppe
Corrao, Giovanni
VALUE IN HEALTH, 2013, 16 (02) : 318 - 324
[39] Central Blood Pressure and Cardiovascular Outcomes in Chronic Kidney Disease
Rahman, Mahboob
Hsu, Jesse Yenchih
Desai, Niraj
Hsu, Chi-yuan
Anderson, Amanda H.
Appel, Lawrence J.
Chen, Jing
Cohen, Debbie L.
Drawz, Paul E.
He, Jiang
Qiang, Pan
Ricardo, Ana C.
Steigerwalt, Susan
Weir, Matthew R.
Wright, Jackson T., Jr.
Zhang, Xiaoming
Townsend, Raymond R.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 13 (04): : 585 - 595
[40] Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension
Weber, Michael A.
Bakris, George L.
Hester, Allen
Weir, Matthew R.
Hua, Tsushung A.
Zappe, Dion
Dahlof, Bjorn
Velazquez, Eric J.
Pitt, Bertram
Jamerson, Kenneth
AMERICAN JOURNAL OF MEDICINE, 2013, 126 (06) : 501 - 508

← 1 2 3 4 5 →